Traditional Testing Infrastructure
High costs
Not only does the cost of test itself put a burden on individuals, hospitals and health insurance companies, but the time lost waiting for diagnosis could be deadly.
|
Lab required
Current diagnostics have complicated procedures requiring specialized technicians, a laboratory and analysis of results.
|
Constraints
Resources are limited for the labs processing lab-based diagnostic kits. A laboratory will reach capacity quickly and end up with a back-log of tests waiting to be processed.
|
Our Testing Infrastructure
MiProbes has a platform technology that is used to develop a testing "bio-ink" for dangerous pathogens and viruses. Our product is significantly faster and cheaper while matching the test quality of the current gold standard.
|
Team
Nina Patrick – CEO
Nina spent the last three years building biotech companies in Silicon Valley. Prior to that, she received her Ph.D. from the University of Arizona in 2015 in Pharmaceutical Sciences where she identified key genes adversely activated and repressed by the drug Depakote, which may explain some of the drug’s side effects. She received her Bachelor’s of Science in Pharmaceutical Chemistry in 2010 from Lehigh University. nina@miprobes.de |
Max Mundt – CTO
Max has a Master's in molecular biotechnology from TU Munich and received his Ph.D. from the Max Planck Institute for terrestrial Microbiology and the Center for Synthetic Microbiology in 2018. Max has extensive experience in genetic circuit design in bacteria and yeast and published on tools to increase accuracy of genetic and signaling pathways in S. cerevisiae. Max co-founded the German Association for Synthetic Biology and can leverage a large network of academic partners in the fields of molecular biology and biotechnology. max@miprobes.de |